Etrasimod for the symptomatic relief of ulcerative colitis

Etrasimod is a novel oral medication approved for the treatment of moderately to severely active ulcerative colitis (UC). It is a selective sphingosine 1-phosphate (S1P) receptor modulator that targets S1P receptors 1, 4, and 5, which play a role in regulating immune cell migration and inflammation. By modulating these receptors, etrasimod helps reduce inflammation in the gastrointestinal tract, leading to symptomatic relief for patients with UC.

### Key Findings from the ELEVATE UC Clinical Programme:

The efficacy of etrasimod for UC was evaluated in the phase III ELEVATE UC clinical trials, which included the ELEVATE UC 52 and ELEVATE UC 12 studies. These trials assessed the impact of etrasimod on key patient-reported symptoms, including stool frequency (SF), rectal bleeding (RB), bowel urgency, and abdominal pain. These symptoms are critical to address, as they significantly impair the quality of life and contribute to treatment dissatisfaction among UC patients.

#### Study Design:

• **Participants**: Adults with moderately to severely active UC.
• **Treatment Groups**: Patients were randomized in a 2:1 ratio to receive either etrasimod 2 mg once daily or a placebo.
• **Endpoints**:
• **Symptomatic remission**: Normalization of RB and SF scores.
• **Symptomatic response**: Significant improvement in RB and SF scores.
• **Complete symptomatic remission**: Resolution of all symptoms, including bowel urgency and abdominal pain.

#### Results:

1. **Rapid and Sustained Symptom Relief**:

• Etrasimod provided significant improvements in symptoms compared to placebo as early as weeks 2 to 4.
• Benefits were sustained through week 52, demonstrating the durability of its therapeutic effects.

2. **Improvement in Key Symptoms**:

• Rapid reductions in rectal bleeding (RB) and stool frequency (SF) were observed in patients treated with etrasimod.
• Clinically meaningful reductions in bowel urgency and abdominal pain were achieved, with higher rates of remission for these symptoms at weeks 12 and 52.

3. **Consistency Across Patient Subgroups**:

• The benefits of etrasimod were observed regardless of baseline disease severity, prior exposure to biologics or JAK inhibitors, or corticosteroid use.
• However, treatment-naïve patients (those who had not received prior biologic or advanced therapy) experienced more pronounced responses.

4. **Impact on Patient Well-Being**:

• By addressing key symptoms like bowel urgency and abdominal pain, etrasimod significantly improved patient well-being and treatment satisfaction.

### Clinical Implications:

Etrasimod represents a promising treatment option for UC patients due to its ability to provide rapid, durable, and clinically meaningful symptom relief. Its oral, once-daily administration is convenient for patients, and its efficacy in reducing debilitating symptoms such as bowel urgency, rectal bleeding, and abdominal pain can lead to improved quality of life.

### Summary:

Etrasimod is a highly effective therapy for achieving symptomatic relief in patients with moderately to severely active ulcerative colitis. The results from the ELEVATE UC trials underscore its ability to deliver rapid and sustained improvements in key symptoms, making it a valuable addition to the therapeutic landscape for UC. Its consistent efficacy across diverse patient populations further supports its role in improving treatment outcomes and patient satisfaction.